|
BMS’ Experimental Liver Cancer Compound Fails Again in Late-Stage Trial
An experimental liver cancer treatment from Bristol-Myers Squibb (BMS) took another hit as it failed to match Bayer and Onyx Pharmaceuticals’ Nexavar as a first-line treatment in a Phase III trial.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
|
Subscribe
Archives